Breaking News Instant updates and real-time market news.

RHHBY

Roche

$29.71

-0.07 (-0.24%)

12:32
10/14/16
10/14
12:32
10/14/16
12:32

FDA approves Genentech's Lucentis prefilled syringe

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration approved the Lucentis, ranibizumab injection, 0.5 mg prefilled syringe, PFS, as a new method of administering the medicine. Like the Lucentis 0.5 mg vial, the 0.5 mg PFS is approved to treat people with wet age-related macular degeneration, AMD, and macular edema after retinal vein occlusion, RVO.The Lucentis PFS is the first syringe prefilled with an anti-VEGF medicine FDA-approved to treat two eye conditions. "The FDA approval of the Lucentis prefilled syringe marks a new milestone in our ongoing commitment to people affected by vision-threatening eye diseases," said Sandra Horning, M.D., chief medical officer and head of Global Product Development. "With the PFS, physicians will have a new option for administering Lucentis to the hundreds of thousands of people in the U.S. diagnosed with either wet AMD or macular edema after RVO." The Lucentis PFS allows physicians to eliminate several steps in the preparation and administration process, including disinfecting the vial, attaching a filter needle, drawing the medicine from the vial using the needle, removing the filter needle from the syringe and replacing with an injection needle. With the Lucentis PFS, physicians attach the injection needle to the syringe and adjust the dose prior to administration. The Lucentis 0.5 mg PFS is expected to be available in early 2017.

  • 19

    Oct

  • 06

    Nov

  • 10

    Nov

RHHBY Roche
$29.71

-0.07 (-0.24%)

09/01/16
BMOC
09/01/16
NO CHANGE
BMOC
Bristol-Myers has negative read through from Roche data, says BMO Capital
BMO Capital analyst Alex Arfaei says that the positive data on Roche's (RHHBY) TECENTRIQ for second line NSCLC is negative for Bristol-Myers' (BMY) cancer drug, Opdivo. The analyst does not think that TECENTRIQ's results will be superior to that of Opdivo, but he believes that Roche's drug appears to have "a significant" benefit in PD-L1 positive patients." He predicts that Roche's drug could take "meaningful market share, particularly outside of the U.S." The analyst keeps a Market Perform rating on Bristol-Myers.
09/07/16
09/07/16
NO CHANGE

BioLineRx partnering with Roche company in cancer therapy research
BioLineRx (BLRX) has entered into a collaboration with Genentech, a member of the Roche (RHHBY) Group, to support several Phase 1b studies investigating BioLineRx's BL-8040 in combination with Atezolizumab, Genentech's anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters, in hematologic malignancies and solid tumors. Under the agreement, Genentech will sponsor and conduct several Phase 1b trials in multiple solid cancer indications. In addition, BioLineRx will sponsor and conduct a Phase 1b study in acute myeloid leukemia patients. The studies are designed to evaluate the safety and efficacy of the combination of BL-8040 and Atezolizumab. Upon completion of the studies, both parties will have the option to expand the collaboration to include a pivotal registration study. Additional details of the collaboration were not disclosed.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.

TODAY'S FREE FLY STORIES

UCTT

Ultra Clean

$24.98

1.32 (5.58%)

10:48
01/18/18
01/18
10:48
01/18/18
10:48
Upgrade
Ultra Clean rating change  »

Follow-up: Ultra Clean…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

T

AT&T

$37.05

0.2 (0.54%)

, ARW

Arrow Electronics

$84.26

0.43 (0.51%)

10:46
01/18/18
01/18
10:46
01/18/18
10:46
Hot Stocks
AT&T, Arrow Electronics announce IoT collaboration »

Arrow Electronics (ARW)…

T

AT&T

$37.05

0.2 (0.54%)

ARW

Arrow Electronics

$84.26

0.43 (0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

QD

Qudian

$12.29

0.1 (0.82%)

10:45
01/18/18
01/18
10:45
01/18/18
10:45
Options
Qudian Inc call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:45
01/18/18
01/18
10:45
01/18/18
10:45
General news
Breaking General news story  »

Week of 1/12 EIA…

10:45
01/18/18
01/18
10:45
01/18/18
10:45
General news
Breaking General news story  »

6-Month Bill Announcement…

10:45
01/18/18
01/18
10:45
01/18/18
10:45
General news
Breaking General news story  »

3-Month Bill Announcement…

CAT

Caterpillar

$168.90

0.4 (0.24%)

, ROSE

Rosehill Resources

$7.96

0.01 (0.13%)

10:39
01/18/18
01/18
10:39
01/18/18
10:39
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

CAT

Caterpillar

$168.90

0.4 (0.24%)

ROSE

Rosehill Resources

$7.96

0.01 (0.13%)

ARNA

Arena Pharmaceuticals

$34.36

0.48 (1.42%)

EA

Electronic Arts

$113.14

1.22 (1.09%)

ATVI

Activision Blizzard

$70.36

1.65 (2.40%)

BBU

Brookfield Business Partners

$36.62

-0.18 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 30

    Jan

  • 08

    Feb

  • 12

    Feb

  • 21

    Feb

  • 22

    Feb

SYMC

Symantec

$27.52

-0.35 (-1.26%)

, JUNO

Juno Therapeutics

$69.25

23.65 (51.86%)

10:39
01/18/18
01/18
10:39
01/18/18
10:39
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

SYMC

Symantec

$27.52

-0.35 (-1.26%)

JUNO

Juno Therapeutics

$69.25

23.65 (51.86%)

CMCSA

Comcast

$41.68

-0.14 (-0.33%)

FSLR

First Solar

$72.00

0.78 (1.10%)

CVX

Chevron

$131.82

-0.54 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 24

    Jan

  • 31

    Jan

  • 02

    Feb

  • 26

    Feb

WMT

Walmart

$103.89

1.19 (1.16%)

, HTZ

Hertz

$22.39

1.33 (6.32%)

10:39
01/18/18
01/18
10:39
01/18/18
10:39
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

WMT

Walmart

$103.89

1.19 (1.16%)

HTZ

Hertz

$22.39

1.33 (6.32%)

ALRM

Alarm.com

$38.27

1.26 (3.40%)

PPL

PPL Corp.

$31.80

0.23 (0.73%)

FLR

Fluor

$59.27

1.14 (1.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 27

    Feb

  • 16

    May

EXAS

Exact Sciences

$47.68

-5.27 (-9.95%)

10:38
01/18/18
01/18
10:38
01/18/18
10:38
Conference/Events
Exact Sciences management to meet with William Blair »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 26

    Feb

UCTT

Ultra Clean

$24.98

1.32 (5.58%)

10:36
01/18/18
01/18
10:36
01/18/18
10:36
Upgrade
Ultra Clean rating change  »

Ultra Clean upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

BHP

BHP Billiton

$49.15

-0.29 (-0.59%)

10:35
01/18/18
01/18
10:35
01/18/18
10:35
Hot Stocks
BHP Billiton considers options for U.S. shale unit »

In an operational review,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNK

Mallinckrodt

$21.19

-1.095 (-4.91%)

10:35
01/18/18
01/18
10:35
01/18/18
10:35
Options
Mallinckrodt put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 08

    Mar

TOL

Toll Brothers

$52.28

0.21 (0.40%)

10:34
01/18/18
01/18
10:34
01/18/18
10:34
Conference/Events
Toll Brothers management to meet with MKM Partners »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

EXEL

Exelixis

$27.49

-2.16 (-7.29%)

, IPSEY

Ipsen

$34.14

2.95 (9.46%)

10:31
01/18/18
01/18
10:31
01/18/18
10:31
Conference/Events
Exelixis and Ipsen co-host a financial community briefing »

Exelixis and Ipsen…

EXEL

Exelixis

$27.49

-2.16 (-7.29%)

IPSEY

Ipsen

$34.14

2.95 (9.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 19

    Jan

  • 19

    Jan

  • 25

    Jan

  • 08

    Feb

  • 15

    Feb

10:30
01/18/18
01/18
10:30
01/18/18
10:30
General news
EIA natural gas storage change for week ending January 12 »

Gas inventories 183 Bcf…

TIVO

TiVo

$14.50

0.1 (0.69%)

, GOOGL

Alphabet Class A

$1,139.10

8.4 (0.74%)

10:26
01/18/18
01/18
10:26
01/18/18
10:26
Hot Stocks
TiVo rises amid expanded patent license agreement with Google »

Shares of TiVo (TIVO) are…

TIVO

TiVo

$14.50

0.1 (0.69%)

GOOGL

Alphabet Class A

$1,139.10

8.4 (0.74%)

GOOG

Alphabet

$1,131.98

10.22 (0.91%)

T

AT&T

$37.33

0.48 (1.30%)

SNE

Sony

$49.09

-0.73 (-1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 23

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 07

    Feb

  • 28

    Feb

  • 18

    Mar

SNAP

Snap

$13.84

0.315 (2.33%)

, FB

Facebook

$177.60

-0.79 (-0.44%)

10:25
01/18/18
01/18
10:25
01/18/18
10:25
Conference/Events
SunTrust Internet & digital media analyst holds analyst/industry conference call »

Internet & Digital…

SNAP

Snap

$13.84

0.315 (2.33%)

FB

Facebook

$177.60

-0.79 (-0.44%)

GOOG

Alphabet

$1,131.98

10.22 (0.91%)

GOOGL

Alphabet Class A

$1,139.10

8.4 (0.74%)

TWTR

Twitter

$23.90

-0.66 (-2.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 23

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 06

    Feb

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

  • 18

    Mar

DIS

Disney

$111.57

-0.4 (-0.36%)

, VIA

Viacom

$37.85

0.95 (2.57%)

10:25
01/18/18
01/18
10:25
01/18/18
10:25
Conference/Events
FBN Securities media analyst to hold an analyst/industry conference call »

Media Analyst Routh,…

DIS

Disney

$111.57

-0.4 (-0.36%)

VIA

Viacom

$37.85

0.95 (2.57%)

TWX

Time Warner

$92.36

0.1916 (0.21%)

CMCSA

Comcast

$41.68

-0.14 (-0.33%)

SPB

Spectrum Brands

$123.47

-1.69 (-1.35%)

DISH

Dish

$45.45

-2.54 (-5.29%)

NFLX

Netflix

$217.50

-4.03 (-1.82%)

AMZN

Amazon.com

$1,295.00

-9.86 (-0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 22

    Jan

  • 24

    Jan

  • 30

    Jan

  • 30

    Jan

  • 06

    Feb

  • 08

    Feb

  • 08

    Feb

  • 18

    Mar

MDXG

MiMedx

$14.09

0.15 (1.08%)

10:25
01/18/18
01/18
10:25
01/18/18
10:25
Conference/Events
MiMedx to hold a conference call »

Chairman & CEO Petit,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

10:25
01/18/18
01/18
10:25
01/18/18
10:25
Conference/Events
Morgan Stanley healthcare analysts hold an analyst/industry conference call »

Healthcare Analyst…

JNPR

Juniper

$28.15

-0.52 (-1.81%)

10:20
01/18/18
01/18
10:20
01/18/18
10:20
Options
Call buyer on weakness in Juniper Networks »

Call buyer on weakness in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

10:20
01/18/18
01/18
10:20
01/18/18
10:20
General news
Today's U.S. reports »

Today's U.S. reports…

ERIC

Ericsson

$7.34

0.4 (5.76%)

, BCE

BCE

$46.36

-0.1301 (-0.28%)

10:18
01/18/18
01/18
10:18
01/18/18
10:18
Hot Stocks
Ericsson to power Bell Canada's next-generation multiscreen TV services »

Ericsson (ERIC) has been…

ERIC

Ericsson

$7.34

0.4 (5.76%)

BCE

BCE

$46.36

-0.1301 (-0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

$NSD

NASDAQ Market Internals

10:17
01/18/18
01/18
10:17
01/18/18
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.